Hair follicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.
Hair loss is linked to the loss of stemcells in hair follicles, and potential treatments include gene editing and microneedling. Discussions also mention using Minoxidil, finasteride, and dermarolling to improve hair growth.
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stemcells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
Hair loss impacts mental health, with treatments like Minoxidil, finasteride, and stem cell transplants discussed. There is hope for future breakthroughs, but current treatments are limited, and awareness is lacking.
The conversation discusses concerns about the potential risk of cancer from creating new hair follicles through microneedling, due to stem cell division. Specific treatments mentioned include microneedling, caffeine-containing anti-hair loss shampoos, and other unspecified topicals.